International Union Against Tuberculosis and Lung Disease

IJTLD March 2017 issue now online

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Read More →

Statement from The Union on bedaquiline access, India

Paris, France, 19 January 2017– Drug-resistant TB is one of the most terrible diseases that any person can ever face. Even when treatment is effective, it is long and very difficult. The health system must do everything in its power to provide access to effective treatments for every patient, with the appropriate treatment depending on the drug susceptibility profile involved in each case. It is essential that drug-sensitivity testing be performed at the outset, so that healthcare workers and patients know which medicines are likely to be effective in treatment and which will not be effective due to resistance. People living with drug-resistant TB should receive only those TB medicines that are likely to be effective in the case of that patient, and they must be treated with multiple medicines, at the same time, to which the TB is susceptible—a treatment approach known as “combination therapy”.

Read More →

IJTLD February 2017 issue now online

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Read More →

December 2016 issue of Public Health Action now online

Public Health Action is the free access, online journal of The International Union Against Tuberculosis and Lung Disease. The journal focuses on tuberculosis, lung health, non-communicable diseases and related public health issues.

Read More →

IJTLD January 2017 issue now online

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Read More →

IJTLD December 2016 issue now online

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Read More →

New links found between TB and non-communicable diseases

Friday, 28 October 2016 (Liverpool, UK) – A series of new research announced today demonstrates linkages between tuberculosis (TB), an infectious disease, and non-communicable diseases including chronic kidney disease and diabetes. In one study, the U.S. Centers for Disease Control and Prevention (CDC) announced research involving 102,072 patients, showing that diabetes is on the rise among TB patients and adding substantially to the costs of hospitalisation. The research was presented at the 47th Union World Conference on Lung Health, convening in Liverpool, UK, 26-29 October 2016.

Read More →

Natural disasters and weak health systems force innovative approaches to delivering TB treatment and care: studies

Saturday, 29 October 2016 (Liverpool, UK) – New research announced today demonstrates the innovation needed to maintain tuberculosis (TB) treatment and care in the face of natural disasters and weak health systems. Studies conducted on TB interventions implemented in the wake of the 2010 Haiti earthquake and the recent West Africa Ebola epidemic, challenges faced in rural areas of China, and new technology used to dramatically reduce stock-outs of essential medicines in Ethiopia were announced today at the 47th Union World Conference on Lung Health, convening 26-29 October in Liverpool, UK.

Read More →

Inaugural Session opens the 47th Union World Conference

In the keynote speech at the Inaugural session Stephen Lewis, the co-founder and co-director of AIDS-Free world, gave a fiery and hard hitting speech, including a list of 10 actions needed to eliminate tuberculosis (TB) for good. He said:

Read More →

Breakthrough study demonstrates far shorter, more effective treatment for MDR-TB, with majority cured

Final results demonstrated nine-month treatment had 82% success rate, compared with previous standard that required more than 20 months of treatment and achieved cure rates below 55%.

Read More →

Page 2 of 7 · Total posts: 10

←First 1 2 3 Last→